Related Experiment Video
Updated: Aug 4, 2026
05:37
Intravitreous Injection for Establishing Ocular Diseases Model
Published on: October 1, 2007
37.0K
Choroidal Effusion following Intravitreal Brolucizumab Injection: A Case Report
Ha Eun Sim1, Jae Suk Kim1, Je Hyung Hwang1
1Department of Ophthalmology, Sanggye Paik Hospital, Inje University College of Medicine, Seoul, Republic of Korea.
Case Reports in Ophthalmology
|May 25, 2022
Summary
Intravitreal brolucizumab injections for wet age-related macular degeneration (AMD) can cause choroidal effusion. This complication may resolve spontaneously, but monitoring is advised.
Area of Science:
- Ophthalmology
- Retinal diseases
Background:
- Wet age-related macular degeneration (AMD) is a leading cause of vision loss.
- Standard anti-vascular endothelial growth factor (anti-VEGF) therapies include aflibercept, ranibizumab, and bevacizumab.
- Brolucizumab is a newer anti-VEGF agent for treating wet AMD.
Observation:
- A 71-year-old man with refractory wet AMD received intravitreal brolucizumab injections.
- Following the second injection, choroidal effusion developed in the treated eye.
- The effusion resolved spontaneously within 12 days without further intervention.
Findings:
- Intravitreal brolucizumab treatment for wet AMD can lead to choroidal effusion.
- The patient experienced initial visual improvement after the first brolucizumab injection.
- Recurrence of wet AMD and subsequent effusion occurred after the second injection.
Implications:
- Choroidal effusion is a potential adverse event associated with intravitreal brolucizumab.
- Close monitoring with fundus examinations is recommended after brolucizumab injections.
- Early detection and management of choroidal effusion may be crucial for visual outcomes.
